Core Viewpoint - Kingsray Biotechnology (01548.HK) announced the appointment of Meng Jiange as a director of Legend Biotech Corporation, effective from January 20, 2026, replacing Zhu Li who will resign on the same date [1]. Group 1 - Kingsray Biotechnology is a company that has a joint venture with Legend Biotech Corporation, which is listed on the NASDAQ Global Select Market [1]. - The appointment of Meng Jiange is part of the governance changes within the board of Legend Biotech [1]. - Zhu Li will step down from the board on the effective date, indicating a transition in leadership [1].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不發表 任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任 何責任。 Genscript Biotech Corporation （於開曼群島註冊成立的有限公司） （股份代號：1548） 自願性公告 傳奇生物科技股份有限公司委任董事 本自願性公告由金斯瑞生物科技股份有限公司（「本公司」）作出。 本公司董事會（「董事會」）欣然宣佈，自2026年1月20日（「生效日期」）起，傳奇 生物科技股份有限公司（「傳奇」，為本公司聯營公司，其股份以美國存託股份形式 於美國納斯達克全球精選市場上市）董事會（「傳奇董事會」）任命孟建革先生 （「孟建革先生」）為董事，初始任期至傳奇2026年周年股東大會為止。孟建革先生 獲委任接替朱力博士於傳奇董事會的職務，朱力博士於生效日期辭任該職務。 2 孟建革先生於生命科學及生物科技領域擁有豐富的高級管理、財務及公司治理經驗。 其現任本公司主席及執行董事，自2010年起即於本公司擔任多個職務。加入本公司前， 孟建革先生曾於Quay Magnesium、 ...

Core Viewpoint - The announcement highlights that Zhongsheng Pharmaceutical's subsidiary, Guangdong Zhongsheng Ruichuang Biotechnology Co., Ltd., has received approval from the National Medical Products Administration for a Phase III clinical trial of its innovative polypeptide drug RAY1225 injection, targeting obesity combined with obstructive sleep apnea [1] Group 1 - RAY1225 injection is an innovative polypeptide drug developed by Zhongsheng Ruichuang, possessing global intellectual property rights [1] - The drug exhibits dual agonistic activity on GLP-1 and GIP receptors, indicating its potential effectiveness in treating obesity-related conditions [1] - RAY1225 injection is characterized by excellent pharmacokinetic properties, allowing for administration once every two weeks, showcasing its long-acting potential [1]

证券日报网讯1月23日，智飞生物（300122）在互动平台回答投资者提问时表示，截至2026年1月20日， 公司普通股股东人数为121021户。 ...

证券日报网讯1月23日，博雅生物（300294）在互动平台回答投资者提问时表示，公司二级市场股票价 格受宏观环境、市场政策、投资者风险偏好等因素影响。公司经营情况请参考公司定期报告。 ...

Group 1: Clinical Data and Impact - The combination therapy of mRNA-4157 and PD-1 inhibitor pembrolizumab significantly reduces the risk of recurrence or death by 49% in high-risk stage III/IV melanoma patients after complete resection, with stable efficacy observed over five years of follow-up [1] - This clinical data is seen as the first long-term survival benefit evidence for mRNA technology in non-infectious diseases, providing a boost to the global cancer immunotherapy field [1] Group 2: mRNA Technology Advantages - mRNA technology allows for the direct translation of specific antigen proteins in the body, inducing a specific immune response, and is considered a third-generation drug development platform [2] - The long-term market potential of mRNA technology is gradually becoming evident, with predictions estimating the global mRNA drug market to reach approximately $18 billion by 2024, potentially growing to over $43 billion in the next decade [2] Group 3: Domestic Companies' Initiatives - Domestic companies are actively laying out their strategies in the mRNA sector, with Ginkgo Bioworks' personalized mRNA cancer vaccine EVM16 having initiated its first human clinical trial in China [3] - Ginkgo Bioworks' vaccine is based on its proprietary AI algorithm system, which has shown the ability to identify both reported and novel tumor antigens [3] Group 4: Key Technological Developments - The nano-delivery system is identified as a critical technological bottleneck in mRNA drug development, significantly affecting drug efficacy and clinical translation [4] - Jitai Technology has developed a liver-targeted LNP delivery system for mRNA encoding bispecific antibodies, which has received orphan drug designation in the U.S. and is currently in clinical development [4] Group 5: Competitive Landscape - Jiachenshihai has multiple technology platforms, including mRNA and self-replicating RNA, and has developed a unique ready-to-use delivery carrier that enhances vaccine accessibility [5] - Other companies such as CSPC Pharmaceutical Group, CanSino Biologics, and Yuyuan Pharmaceutical have also reported their involvement in mRNA technology platforms [5]

Core Viewpoint - The company has proactively and prudently adjusted the pricing of its shingles vaccine to activate market potential and fulfill corporate social responsibility, aiming to alleviate the economic burden of vaccination, especially for the elderly population [1] Group 1 - The company is focused on expanding the coverage of its shingles vaccine among target populations, particularly the middle-aged and elderly [1] - The company is enhancing its market penetration by improving channel distribution and increasing terminal coverage [1] - The adjustments in pricing are intended to promote broader access to the vaccine while maintaining existing product coverage [1]

（文章来源：每日经济新闻） 每经AI快讯，康华生物1月23日晚间公告，预计2025年度归母净利润1.91亿元~2.33亿元，同比下降 41.55%~52.09%，上年同期归母净利润为3.99亿元。 ...

2026年1月21日，北京普祺医药科技股份有限公司（简称：普祺医药）正式向港交所递交IPO申请，中信证券与民银资本担任联席保荐人。 这家深耕免疫炎症领域的零主营收入Biotech，选择借道港股18A规则开启资本化新征程，而这距其撤回北交所IPO申请仅三个月。 截至2025年9月，普祺医药现金及现金等价物仅1.55亿元，按当前消耗速度怕是无法维持一年正常经营。 普祺医药的核心价值，正扎根于免疫炎症赛道的蓝海市场与自身产品的差异化优势。 这一领域是全球第三大慢性病市场，全球自身免疫性疾病药物市场2033年预计达2170亿美元，过敏性疾病市场将至1311亿美元。 其中，中国市场增速更显著，两大领域2033年规模将分别达2196亿元、2938亿元，特应性皮炎、过敏性鼻炎患者分别超7500万、2.5亿，且现有治疗手段存 在疗效、安全或价格短板。 行业研发正朝着精准靶向、局部递送方向发展，口服JAK抑制剂的全身副作用让局部给药成为新风口。 普祺医药的上市之路曲折且具代表性，2022年12月新三板挂牌为冲击北交所铺路，2024年3月启动北交所辅导，2025年6月完成B轮超3亿融资后递交申请， 却因四个多月未获受理最终主动撤 ...

Group 1 - The core point of the article is that Sinovac Biotech Ltd. has received approval from the Nasdaq Hearing Committee to maintain its listing status on the Nasdaq Global Market, provided it submits its financial reports by May 11, 2026 [1][3] - The company must complete the submission of its annual financial report for the fiscal year ending December 31, 2024, and the interim financial report for the second quarter of 2025 by the specified deadline [4][5] - Sinovac has engaged Zhonghua Certified Public Accountants to conduct independent audits and is working collaboratively to expedite the audit and reporting process [1][4] Group 2 - Sinovac's delisting crisis began over two months ago when it received a delisting notice from Nasdaq due to its failure to submit the required annual report on time [4][6] - The company reported a significant increase in revenue and net profit in 2021, with total revenue reaching 135.487 billion yuan, a year-on-year increase of 3694.36%, and net profit of 59.212 billion yuan, a year-on-year increase of 7571.97% [6][7] - However, the demand for COVID-19 vaccines has sharply declined, leading to a significant drop in revenue and net profit in 2022 and 2023, with revenue decreasing by 92.30% and 69.97%, and net profit decreasing by 98.66% and 187.75% respectively [7] Group 3 - Sinovac has a diverse product pipeline, including vaccines for hepatitis A, influenza, varicella, and inactivated polio vaccine, with recent approvals for new products such as the 23-valent pneumococcal polysaccharide vaccine [7] - The international market is becoming a new growth area for Sinovac, with recent successes in obtaining WHO pre-certification for certain vaccines and winning exclusive bids for influenza vaccine orders in Chile [7] - Internal governance issues remain unresolved, with ongoing conflicts between management and significant shareholders affecting the company's stability and operations [7]